Successful use of biotherapy with somatostatin analogues in the treatment of a patient with multiple endocrine neoplasia type 1

The syndrome of multiple endocrine neoplasia type I, MEN-1, or Wermer’s syndrome, occupies a separate place in the group of neuroendocrine tumors. Being a genetic, family-determined disease and having a transmission rate of 50%, it is manifested by multiple neoplasms of various malignant potential in many organs. Given the trend towards personalization of treatment, specialists in various fields are constantly looking for improved diagnostics and new methods of treatment. We present our own experience in the treatment of MEN-1 syndrome with somatostatin analogues. The patient, born in 1972, was observed by an endocrinologist at the age of 22, when a pituitary microadenoma was detected. After 18 years, a pancreatic tumor was detected, which was successfully removed. Histological and immunohistochemical studies verified a Grade 1 neuroendocrine tumor. Control computed tomography revealed multiple masses in the head and tail of the pancreas. Given the condition, patients since 2013 have been prescribed biotherapy with an analogue of somatostatin – octreotide. However, taking the drug was not regular, and the patient noted a deterioration in her condition. In 2019, by decision of the council, biotherapy with Lanreotide was prescribed. Even taking into account irregular examinations due to absenteeism, the control examination in 2022 showed normalization of the levels of chromogranin A and serotonin, the absence of new tumor foci and the progression of those present during Positron emission tomography. Thus, a multidisciplinary approach and the appointment of adequate therapy helps to improve the quality of life and stabilize patients with MEN-1 syndrome.

1. Dasari A., Shen C., Halperin D., Zhao B., Zhou S., Xu Y. et al. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol. 2017;3(10):1335–1342. https://doi.org/10.1001/jamaoncol.2017.0589.

2. Pieterman C.R.C., Valk G.D. Update on the clinical management of multiple endocrine neoplasia type 1. Clin Endocrinol (Oxf). 2022;97(4):409–423. https://doi.org/10.1111/cen.14727.

3. Thakker R.V., Newey P.J., Walls G.V., Bilezikian J., Dralle H., Ebeling P.R. et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab. 2012;97(9):2990–3011. https://doi.org/10.1210/jc.2012-1230.

4. Sadowski S.M., Triponez F. Management of pancreatic neuroendocrine tumors in patients with MEN 1. Gland Surg. 2015;4(1):63–68. https://doi.org/10.3978/j.issn.2227-684X.2014.12.01.

5. Dedov I.I., Melnichenko G.A., Mokrysheva N.G., Andreeva E.N., Antsiferov M.B., Beltsevich D.G. et al. Draft of clinical guidelines for the diagnosis and treatment of primary hyperparathyroidism in adult patients. Endocrine Surgery. 2022;16(4):5–54. (In Russ.) https://doi.org/10.14341/serg12790.

6. Ignatyuk V.G., Britvin T.A., Podrez D.V., Gurevich L.E. Multiple endocrine neoplasia type 1 with primary hyperparathyroidism, pancreatic insulinoma and portal gastrinoma (case report). Annals of HPB Surgery. 2018;23(3):57–63. (In Russ.) https://doi.org/10.16931/1995-5464.2018357-63.

7. Pieterman C.R., Conemans E.B., Dreijerink K.M., de Laat J.M., Timmers H.T., Vriens M.R., Valk G.D. Thoracic and duodenopancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1: natural history and function of menin in tumorigenesis. Endocr Relat Cancer. 2014;21(3):R121–R142. https://doi.org/10.1530/ERC-13-0482.

8. Lipatenkova A.K., Dzeranova L.K., Pigarova E.A., Rozhinskaya L.Y., Kochatkov A.V. Clinical case: multiple endocrine neoplasia type 1 (MEN 1). Obesity and Metabolism. 2012;9(4):44–47. (In Russ.) https://doi.org/10.14341/2071-8713-5129.

9. Boharoon H., Grossman A. A New Medical Therapy for Multiple Endocrine Neoplasia Type 1? touchREV Endocrinol. 2022;18(2):86–88. https://doi.org/10.17925/EE.2022.18.2.86.

10. Sesti F., La Salvia A., Grinzato C. Mazzilli R., Faggiano A. L’approccio con analoghi della somatostatina nelle neoplasie neuroendocrine associate a sindromi neoplastiche multi-endocrine ereditarie. L’Endocrinologo. 2021;22:423–428. https://doi.org/10.1007/s40619-021-00952-y.

11. La Salvia A., Sesti F., Grinzato C., Mazzilli R., Tarsitano M.G., Giannetta E., Faggiano A. Somatostatin Analogue Therapy in MEN1-Related Pancreatic Neuroendocrine Tumors from Evidence to Clinical Practice: A Systematic Review. Pharmaceuticals (Basel). 2021;14(10):1039. https://doi.org/10.3390/ph14101039.

12. Pavel M., Cwikła J.B., Lombard-Bohas C., Borbath I., Shah T., Pape U-F. et al. 1162MO Efficacy and safety of lanreotide autogel (LAN) 120 mg every 14 days in progressive pancreatic or midgut neuroendocrine tumours (NETs): CLARINET FORTE study results. Ann Oncol. 2020;(Suppl. 4):S773. https://doi.org/10.1016/j.annonc.2020.08.1375.

13. Faggiano A., Modica R., Lo Calzo F., Camera L., Napolitano V., Altieri B. et al. Lanreotide Therapy vs Active Surveillance in MEN1-Related Pancreatic Neuroendocrine Tumors < 2 Centimeters. J Clin Endocrinol Metab. 2020;105(1):dgz007. https://doi.org/10.1210/clinem/dgz007.

14. Egorov A.V., Kondrashin S.A., Fominikh E.V., Musaev G.Kh., Gitel E.P., Gurevich L.E. et al. Analogs of somatostatin in diagnostics and managements of neuroendocrine tumors of neuroendocrine tumors. Annals of HPB Surgery. 2009;14(4):71–78. (In Russ.) Available at: https://www.elibrary.ru/item.asp?edn=ofrnsh&ysclid=ljobdkp7zd593917498.

15. Egorov A.V., Vasilyev I.A., Kondrashin S.A., Gurevich L.E., Fominyh E.V., Mironova A.V. Surgical management of pancreatic neuroendocrine tumors. Tavricheskiy Mediko-Biologicheskiy Vestnik. 2020;23(2):69–74. (In Russ.) Available at: https://www.elibrary.ru/item.asp?id=44783331&ysclid=ljoboxmhc2466867176.

16. Gurevich L.E., Korsakova N.A., Voronkova I.A., Ashevskaya V.E., Titov A.G., Kogoniya L.M. et al. Immunohistochemical determination of expression of somatostatin receptors types 1, 2A, 3 and 5 in neuroendocrine tumors of various localization and grade. Almanac of Clinical Medicine. 2016;44(4):378–390. (In Russ.) https://doi.org/10.18786/2072-0505-2016-44-4-378-390.

17. Anlauf M., Garbrecht N., Bauersfeld J., Schmitt A., Henopp T., Komminoth P. et al. Hereditary neuroendocrine tumors of the gastroenteropancreatic system. Virchows Arch. 2007;451(Suppl. 1):S29–S38. https://doi.org/10.1007/s00428-007-0450-3.

18. Caplin M.E., Pavel M., Phan A.T., Ćwikła J.B., Sedláčková E., Thanh X.T. et al. Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study. Endocrine. 2021;71(2):502–513. https://doi.org/10.1007/s12020-020-02475-2.

19. Frost M., Lines K.E., Thakker R.V. Current and emerging therapies for PNETs in patients with or without MEN1. Nat Rev Endocrinol. 2018;14(4):216–227. https://doi.org/10.1038/nrendo.2018.3.

20. Falconi M., Eriksson B., Kaltsas G., Bartsch D.K., Capdevila J., Caplin M. et al. ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors. Neuroendocrinology. 2016;103(2):153–171. https://doi.org/10.1159/000443171.